Insider Selling: Beta Bionics (NASDAQ:BBNX) CFO Sells 20,000 Shares of Stock

by · The Cerbat Gem

Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) CFO Stephen Feider sold 20,000 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer directly owned 42,614 shares of the company’s stock, valued at approximately $1,258,391.42. The trade was a 31.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Stephen Feider also recently made the following trade(s):

  • On Tuesday, December 2nd, Stephen Feider sold 1,427 shares of Beta Bionics stock. The stock was sold at an average price of $29.34, for a total transaction of $41,868.18.

Beta Bionics Price Performance

Beta Bionics stock traded up $0.32 during midday trading on Monday, hitting $29.57. The company’s stock had a trading volume of 473,618 shares, compared to its average volume of 627,559. The company has a market cap of $1.30 billion and a price-to-earnings ratio of -6.77. Beta Bionics, Inc. has a 1-year low of $8.89 and a 1-year high of $32.71. The company has a 50-day moving average price of $28.97 and a two-hundred day moving average price of $21.93.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last announced its earnings results on Tuesday, October 28th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.12. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%. The company had revenue of $27.25 million for the quarter, compared to analysts’ expectations of $23.92 million.

Analyst Ratings Changes

A number of research firms have recently weighed in on BBNX. Bank of America upped their target price on Beta Bionics from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Monday. Truist Financial boosted their price target on Beta Bionics from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. Lake Street Capital reissued a “buy” rating and issued a $35.00 target price on shares of Beta Bionics in a report on Wednesday, October 29th. Finally, Wall Street Zen upgraded shares of Beta Bionics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 1st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.70.

View Our Latest Research Report on BBNX

Hedge Funds Weigh In On Beta Bionics

A number of institutional investors have recently added to or reduced their stakes in BBNX. GPS Wealth Strategies Group LLC boosted its position in Beta Bionics by 45.0% in the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after buying an additional 450 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after acquiring an additional 1,594 shares during the last quarter. Verition Fund Management LLC boosted its holdings in shares of Beta Bionics by 4.0% during the 3rd quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock valued at $940,000 after acquiring an additional 1,823 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Beta Bionics by 139.1% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after acquiring an additional 1,863 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Beta Bionics by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,558 shares of the company’s stock worth $343,000 after acquiring an additional 2,205 shares during the last quarter.

About Beta Bionics

(Get Free Report)

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

Further Reading